Understand the source comparison
Best Peptides for Metabolism Boost: Mechanism Comparison
Ipamorelin (GH Secretagogue) Ghrelin receptor agonist → endogenous GH pulse → IGF-1 → hormone-sensitive lipase activation Lipolysis, lean mass preservation, protein synthesis 200–300 mcg SC nightly pre-sleep Individuals with low-normal IGF-1 seeking fat loss w
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Ipamorelin (GH Secretagogue)
- Ghrelin receptor agonist → endogenous GH pulse → IGF-1 → hormone-sensitive lipase activation
- Lipolysis, lean mass preservation, protein synthesis
- 200–300 mcg SC nightly pre-sleep
- Individuals with low-normal IGF-1 seeking fat loss with muscle retention during caloric deficit
- Most selective GH secretagogue with minimal cortisol/prolactin cross-reactivity. Ideal for sustained protocols without desensitization
- Hexarelin (GH Secretagogue)
- Ghrelin receptor agonist → 5–7× baseline GH release
- Acute lipolysis, fatty acid mobilization
- 100 mcg SC pre-fasted training, 5 days on / 2 days off
- Acute metabolic boost during fasted training or before contest prep phases
- Strongest acute GH response but requires cycling to prevent receptor desensitization. Not sustainable long-term
- CJC-1295/Ipamorelin Blend
- GHRH analogue (sustained baseline GH) + GHS-R1a agonist (pulsatile GH)
- Dual pathway: baseline metabolic rate + acute lipolytic pulses
- 1–2 mg CJC weekly + 200–300 mcg ipamorelin nightly
- Individuals seeking both sustained metabolic elevation and training-synced fat oxidation
- Best of both worlds. CJC provides week-long baseline lift while ipamorelin creates controllable GH spikes
- Semaglutide (GLP-1 Agonist)
- GLP-1 receptor agonist → glucose-dependent insulin secretion + slowed gastric emptying
- Insulin sensitivity, glucose disposal, substrate partitioning
- 2.4 mg SC weekly (titrated from 0.25 mg)
- Individuals with A1C >5.7%, fasting insulin >8 μIU/mL, or impaired glucose tolerance
- Gold standard for insulin resistance reversal. Metabolic benefit scales with degree of pre-existing insulin dysfunction
- Tirzepatide (Dual GIP/GLP-1)
- Dual incretin agonist → amplified insulin sensitivity + adipocyte-direct lipolysis via GIP
- Glucose control + fat oxidation independent of appetite suppression
- 15 mg SC weekly (titrated from 2.5 mg)
- Individuals with metabolic syndrome, high triglycerides, or plateaued fat loss despite caloric deficit
- Produces greater fat loss than GLP-1 monotherapy. GIP component adds lipolytic signaling beyond glucose control
- MOTS-c (Mitochondrial Peptide)
- AMPK activation → mitochondrial biogenesis + oxidative phosphorylation efficiency
- Cellular ATP production, fatty acid oxidation, metabolic flexibility
- 5–10 mg SC twice weekly
- Individuals with metabolic inflexibility (inability to switch between glucose and fat oxidation efficiently)
- Addresses root metabolic dysfunction at the mitochondrial level. Requires adequate substrate and recovery to amplify